Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Pulmonary Fibrosis Treatment Market size was over USD 3.25 billion in 2024 and is anticipated to cross USD 7.1 billion by 2037, growing at more than 6.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of pulmonary fibrosis treatment is estimated at USD 3.42 billion.
As per the Pulmonary Fibrosis Foundation, the disease affects about 1 out of 200 adults above the age of 70 years in the United States. Moreover, around 50,000 new cases of pulmonary fibrosis are diagnosed in the country every year.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of pulmonary fibrosis treatment is estimated at USD 3.42 billion.
Pulmonary Fibrosis Treatment Market size was over USD 3.25 billion in 2024 and is anticipated to cross USD 7.1 billion by 2037, growing at more than 6.2% CAGR during the forecast period i.e., between 2025-2037.
Asia Pacific industry is predicted to dominate majority revenue share by 2037, driven by growing presence of leading companies involved in research and development activities for the manufacturing of effective drugs.
The major players in the market are Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, MediciNova, Inc., Genentech, Inc., Cipla Inc., Biogen and Galapagos NV.
